Guideline for management of vasculitis syndrome (JCS 2008): Digest version

Circulation Journal

Volumn 75, Issue 2, 2011, Pages 474-503

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BERAPROST; CILOSTAZOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LIMAPROST; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; PROSTAGLANDIN E1; PROSTAVASIN; SARPOGRELATE; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTERY GRAFT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BED REST; BLOOD VESSEL BIOPSY; BUERGER DISEASE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CRYOGLOBULINEMIA; DIFFERENTIAL DIAGNOSIS; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ENDARTERECTOMY; GENE THERAPY; GEOGRAPHY; HUMAN; INCIDENCE; KINESIOTHERAPY; LABORATORY DIAGNOSIS; LIMB ISCHEMIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHYSICAL EXAMINATION; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; RECOMMENDED DRUG DOSE; REVASCULARIZATION; RHEUMATOID VASCULITIS; SMALL VESSEL VASCULITIS; SYMPATHECTOMY; TEMPORAL ARTERITIS; THERAPY RESISTANCE; THORACIC AORTA ANEURYSM; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

ADULT; CARDIOVASCULAR AGENTS; FEMALE; GIANT CELL ARTERITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYARTERITIS NODOSA; SYNDROME; SYSTEMIC VASCULITIS; TAKAYASU ARTERITIS; THROMBOANGIITIS OBLITERANS; VASCULITIS;

EID: 79251584054     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-88-0007     Document Type: Article

References (154)

1. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, et al. Guidelines on the management and treatment of glucocorticoid- induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005; 23: 105-109.
2. Orimo H, editor. Guidelines for the prevention and treatment of osteoarthritis, 2006 edition. Tokyo: Life Science Publishing, 2006 (in Japanese).
3. Hashimoto H, editor. Guidelines for diagnosis and treatment of complications of immune diseases and their treatment. Study group on Complications of Immune Diseases and Their Treatment in the MHLW Immune/Allergy Disease Prevention and Treatment Research Project. 2005 (in Japanese).
4. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332-1337.
5. Takayasu M. A case of paradoxical changes in the central retinal arteries. J Jpn Ophthalmol Soc 1908; 12: 554-555 (in Japanese).
6. Niimi Y. A case of Takayasu disease. Sogo Ganka 1942; 36: 1402 (in Japanese).
7. Shimizu K, Sano K. Pulseless disease. J Neuropathol Clin Neurol 1951; 1: 37-47.
8. Ueda H, Saito Y, Ito Y, Yamaguchi H, Sugiura M, Morooka S. Immunological studies of aortitis syndrome. Jpn Heart J 1967; 8: 4-18.
9. Kobayashi Y, Numano F, Nakajima N, Yasuda K, Nakabayashi K, Yutani C. Subcommittee report on clinical practice of large-vessel vasculitis-Takayasu arteritis (aortitis syndrome). In: Hashimoto H, chair. Report by the Intractable Vasculitis Research Group of the MHLW Specific Immune Disease Study Group in 1998. 1999; 171-184 (in Japanese).
10. Numano F, Kobayashi Y. Takayasu arteritis and Buerger Disease IV. Int J Cardiol 2000; 75(Suppl): 1-192.
11. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 1999; 285: 727-729.
12. Seko Y, Minota S, Kawasaki A, Shinkai Y, Maeda K, Yagita H, et al. Perforin-secreting killer cell infiltration and expression of a 65- kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J Clin Invest 1994; 93: 750-758.
13. Seko Y, Sugishita K, Sato O, Takagi A, Tada Y, Matsuo H, et al. Expression of costimulatory molecules (4-1BBL and Fas) and major histocompatibility class I chain-related A (MICA) in aortic tissue with Takayasu's arteritis. J Vasc Res 2004; 41: 84-90.
14. Yutani C. Takayasu arteritis. In: Ozaki S, Yoshiki T, editors. Atlas of arteritis. Intractable Vasculitis Study Group of the MHLW Intractable Disease Treatment Research Project in 2005. 2005; 5-8 (in Japanese).
15. Kobayashi Y, Numano F. Takayasu arteritis. In: Hashimoto H, editor. Vasculitis. Tokyo: Asakura Publishing, 2001; 192-198 (in Japanese).
16. Yutani C. Pathology of arteritis syndrome. Byori to Rinsho 2003; 21: 1007-1013 (in Japanese).
17. Kobayashi Y. Takayasu arteritis. In: Hashimoto H, chair. Treatment manual for intractable vasculitis. Intractable Vasculitis Research Group of the MHLW Specific Disease Research Project in 2002. 2002; 1-9 (in Japanese).
18. Ito I. Medical treatment of Takayasu arteritis. Heart Vessels Suppl 1992; 7: 133-137.
19. Moriwaki R, Numano F. Takayasu arteritis: Follow-up studies for 20 years. Heart Vessels Suppl 1992; 7: 138-145.
20. Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study. Arthritis Rheum 1998; 41: 1835-1844.
21. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-582.
22. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 2003; 30: 1793-1798.
23. Wada K, Takada M, Ueda T, Ochi H, Morishita H, Hanatani A, et al. Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients. Circ J 2006; 70: 1307-1311.
24. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
25. Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis. Clin Exp Immunol 2004; 138: 369-374.
26. Voltarelli JC, Oliveira MC, Stracieri AB, Godoi DF, Moraes DA, Coutinho MA, et al. Haematopoietic stem cell transplantation for refractory Takayasu's arteritis. Rheumatology (Oxford) 2004; 43: 1308-1309.
27. Weaver FA, Yellin AE, Campen DH, Oberg J, Foran J, Kitridou RC, et al. Surgical procedures in the management of Takayasu's arteritis. J Vasc Surg 1990; 12: 429-437; discussion 438-439.
28. Takagi A, Tada Y, Sato O, Miyata T. Surgical treatment for Takayasu's arteritis: A long-term follow-up study. J Cardiovasc Surg (Torino) 1989; 30: 553-558.
29. Kimoto S. The history and present status of aortic surgery in Japan, particularly for aortitis syndrome. J Cardiovasc Surg (Torino) 1979; 20: 107-126.
30. Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994; 90: 1855-1860.
31. Enomoto S, Miyamoto T, Shimada I, Pak C, Shinkura N, Ohno N, et al. Surgical therapy for aortic regurgitation due to aortitis syndrome- Effectiveness and extended indication of Bentall's operation. Jpn J Thorac Cardiovasc Surg 1992; 40: 500-505 (in Japanese).
32. Ando M, Kosakai Y, Okita Y, Nakano K, Kitamura S. Surgical treatment for aortic regurgitation caused by Takayasu's arteritis. J Card Surg 1998; 13: 202-207.
33. Ando M, Okita Y, Sasako Y, Kitamura S, Matsuo H. Evaluation of the results surgical treatment for dilative lesions associated with Takayasu's arteritis. Int J Angiol 2000; 9: 194-197.
34. Isomura T, Hisatomi K, Yanagi I, Shimada S, Uraguchi K, Aoyagi S, et al. The surgical treatment of aortic regurgitation secondary to aortitis. Ann Thorac Surg 1988; 45: 181-185.
35. Suzuki A, Amano J, Tanaka H, Sakamoto T, Sunamori M. Surgical consideration of aortitis involving the aortic root. Circulation 1989; 80(Suppl 1): I222-I232.
36. Young JA, Sengupta A, Khaja FU. Coronary arterial stenosis, angina pectoris and atypical coarctation of the aorta due to nonspecific arteritis: Treatment with aortocoronary bypass graft. Am J Cardiol 1973; 32: 356-360.
37. Cipriano PR, Silverman JF, Perlroth MG, Griepp RB, Wexler L. Coronary arterial narrowing in Takayasu's aortitis. Am J Cardiol 1977; 39: 744-750.
38. Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE. Takayasu's arteritis: Clinical study of 107 cases. Am Heart J 1977; 93: 94-103.
39. Makino N, Orita Y, Takeshita A, Nakamura M, Matsui K, Tokunaga K. Coronary arterial involvement in Takayasu's disease. Jpn Heart J 1982; 23: 1007-1013.
40. Ohara K, Kasegawa T, Ando T, Kawazoe K, Kosakai Y, Kaku K, et al. Surgical treatment of coronary artery disease associated with aortitis syndrome. Kyobu Geka 1986; 39: 423-431 (in Japanese).
41. Tada Y, Sato O, Ohshima A, Miyata T, Shindo S. Surgical treatment of Takayasu arteritis. Heart Vessels Suppl 1992; 7: 159-167.
42. Sasaki S, Kubota S, Kunihara T, Shiiya N, Yasuda K. Surgical experience of the thoracic aortic aneurysm due to Takayasu's arteritis. Int J Cardiol 2000; 75(Suppl 1): S129-S134.
43. Fukushima K. Aneurysmal dilatation in Takayasu's arteritis: Especialy, the long-term results of surgical and non-surgical treatment (author's transl). Nippon Kyobu Geka Gakkai Zasshi 1977; 25: 1622-1642 (in Japanese).
44. Ando M, Okita Y, Tagusari O, Kitamura S, Matsuo H. A surgically treated case of Takayasu's arteritis complicated by aortic dissections localized in the ascending and abdominal aortae. J Vasc Surg 2000; 31: 1042-1045.
45. Seko Y, Yazaki Y, Uchimura H, Isobe M, Tsuchimochi H, Kurabayashi M, et al. A case of Takayasu's disease with ruptured carotid aneurysm. Jpn Heart J 1986; 27: 523-531.
46. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005; 17: 16-24.
47. Parra JR, Perler BA. Takayasu's disease. Semin Vasc Surg 2003; 16: 200-208.
48. Tyagi S, Verma PK, Gambhir DS, Kaul UA, Saha R, Arora R. Early and long-term results of subclavian angioplasty in aortoarteritis (Takayasu disease): Comparison with atherosclerosis. Cardiovasc Intervent Radiol 1998; 21: 219-224.
49. Bali HK, Bhargava M, Jain AK, Sharma BK. De novo stenting of descending thoracic aorta in Takayasu arteritis: Intermediate-term follow-up results. J Invasive Cardiol 2000; 12: 612-617.
50. Tyagi S, Kaul UA, Arora R. Endovascular stenting for unsuccessful angioplasty of the aorta in aortoarteritis. Cardiovasc Intervent Radiol 1999; 22: 452-456.
51. Sharma S, Bahl VK, Saxena A, Kothari SS, Talwar KK, Rajani M. Stenosis in the aorta caused by non-specific aortitis: Results of treatment by percutaneous stent placement. Clin Radiol 1999; 54: 46-50.
52. Pajari R, Hekali P, Harjola PT. Treatment of Takayasu's arteritis: An analysis of 29 operated patients. Thorac Cardiovasc Surg 1986; 34: 176-181.
53. Wang ZG, Gu YQ, Zhang J, Li JX, Yu HX, Luo T, et al. Challenges in management of cerebral ischemia due to Takayasu's arteritis. Zhonghua Wai Ke Za Zhi 2006; 44: 14-17 (in Chinese).
54. Taketani T, Miyata T, Morota T, Takamoto S. Surgical treatment of atypical aortic coarctation complicating Takayasu's arteritis- experience with 33 cases over 44 years. J Vasc Surg 2005; 41: 597-601.
55. Kumar A, Dubey D, Bansal P, Sanjeevan KV, Gulati S, Jain S, et al. Surgical and radiological management of renovascular hypertension in a developing country. J Urol 2003; 170: 727-730.
56. Weaver FA, Kumar SR, Yellin AE, Anderson S, Hood DB, Rowe VL, et al. Renal revascularization in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg 2004; 39: 749-757.
57. Mishima Y. Buerger's disease. In: Kimoto S, editor. Modern surgical practice (annual supplement). Tokyo: Nakayama Shoten, 1978; 1978-D: 261-277 (in Japanese).
58. Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000; 343: 864-869.
59. Gulati SM, Madhra K, Thusoo TK, Nair SK, Saha K. Autoantibodies in thromboangiitis obliterans (Buerger's disease). Angiology 1982; 33: 642-651.
60. Adar R, Papa MZ, Halpern Z, Mozes M, Shoshan S, Sofer B, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983; 308: 1113-1116.
61. Roncon de Albuquerque R, Delgado L, Correia P, Torrinha JF, Serrão D, Braga A. Circulating immune complexes in Buerger's disease. Endarteritis obliterans in young men. J Cardiovasc Surg (Torino) 1989; 30: 821-825.
62. Majewski W, Marszalek A, Staniszewiski R, Majewski P, Zapalski S, Biczysko W. Clinical and morphological aspects of Buerger's disease. Int Angiol 1997; 16: 239-244.
63. Eichhorn J, Sima D, Lindschau C, Turowski A, Schmidt H, Schneider W, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci 1998; 315: 17-23.
64. Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg 2004; 39: 176-180.
65. Buerger L. Thrombo-angitis obliterance: A study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci 1908; 136: 567-580.
66. Haga E. Über spontane Gangren. Arch Path Anat 1898; 152: 26-60.
67. Allen E, Brown G. Thrimbo-angiitis obliterans: A clinical study of 200 cases. Ann Intern Med 1928; 1: 535-549.
68. Iwai T, Inoue Y, Umeda M, Huang Y, Kurihara N, Koike M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 2005; 42: 107-115.
69. Bozkurt AK, Koksal C, Ercan M. The altered hemorheologic parameters in thromboangiitis obliterans: A new insight. Clin Appl Thromb Hemost 2004; 10: 45-50.
70. Kimura A, Kobayashi Y, Takahashi M, Ohbuchi N, Kitamura H, Nakamura T, et al. MICA gene polymorphism in Takayasu's arteritis and Buerger's disease. Int J Cardiol 1998; 66(Suppl 1): S107-S113; discussion S115.
71. McLoughlin GA, Helsby CR, Evans CC, Chapman DM. Association of HLA-A9 and HLA-B5 with Buerger's disease. Br Med J 1976; 2: 1165-1166.
72. Smolen JS, Youngchaiyud U, Weidinger P, Kojer M, Endler AT, Mayr WR, et al. Autoimmunological aspects of thromboangiitis obliterans (Buerger's disease). Clin Immunol Immunopathol 1978; 11: 168-177.
73. de Moerloose P, Jeannet M, Mirimanoff P, Bouvier CA. Evidence for an HLA-linked resistance gene in Buerger's disease. Tissue Antigens 1979; 14: 169-173.
74. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000; 56: 522-529.
75. Sasaki S, Sakuma M, Kunihara T, Yasuda K. Distribution of arterial involvement in thromboangiitis obliterans (Buerger's disease): Results of a study conducted by the Intractable Vasculitis Syndromes Research Group in Japan. Surg Today 2000; 30: 600-605.
76. Shigematsu H, Shigematsu K. Factors affecting the long-term outcome of Buerger's disease (thromboangiitis obliterans). Int Angiol 1999; 18: 58-64.
77. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002; 360: 427-435.
78. Iwatsuka Y, Sakurai T, Yamamoto K, Shionoya S. Epidural stimulating electrode method for the treatment of Buerger's disease. In: Tanabe T, chair. Report of the Intractable Vasculitis Study Group of the MHLW in 1990. 1991; 67-69 (in Japanese).
79. Shigematsu K, Shigematsu H, Yasuda K. Long-term prognosis of Buerger disease. In: Summary and individual research reports by the Intractable Vasculitis Study Group of the MHLW Specific Disease Reserch Project in 2003. 2004; 115-119 (in Japanese).
80. Nordborg E, Nordborg C. Giant cell arteritis: Strategies in diagnosis and treatment. Curr Opin Rheumatol 2004; 16: 25-30.
81. Hellmann DB. Temporal arteritis: A cough, toothache, and tongue infarction. JAMA 2002; 287: 2996-3000.
82. Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: The first government-supported nationwide survey. Arthritis Rheum 2003; 49: 594-598.
83. Dasgupta B, Hassan N. Giant cell arteritis: Recent advances and guidelines for management. Clin Exp Rheumatol 2007; 25(1 Suppl 44): S62-S65.
84. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-1128.
85. Matsui Y. Temporal arteritis and ischemic optic neuropathy. Nihon No Ganka 2007; 78: 387-390 (in Japanese).
86. Taira Y, Matsuo T, Matsuo N. A case of temporal arteritis with anterior ischemic optic neuropathy. Jpn J Clin Ophthalmol 1996; 50: 1659-1663 (in Japanese).
87. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: Ocular manifestations. Am J Ophthalmol 1998; 125: 521-526.
88. Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17: 27-35.
89. Schmidt D. Ocular ichemia syndrome-a malignant course of giant cell arteritis. Eur J Med Res 2005; 10: 233-242.
90. Penn H, Dasgupta B. Giant cell arteritis. Autoimmun Rev 2003; 2: 199-203.
91. Wilke WS, Hoffman GS. Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am 1995; 21: 59-71.
92. Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986; 220: 465-469.
93. Bengtsson BA, Malmvall BE. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica: A followup study on ninety patients treated with corticosteroids. Acta Med Scand 1981; 209: 337-345.
94. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheu matica and giant-cell arteritis. N Engl J Med 2002; 347: 261-271.
95. Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: New light on old controversies. Ophthalmologica 2003; 217: 239-259.
96. Tsuchida N. Temporal arteritis. In: Ophthalmology Practice Guide Editing Committee, editor. Ophthalmology practice guide. Tokyo: Bunkodo, 2004; 659-660 (in Japanese).
97. Kobayashi S. Temporal arteritis (Giant cell arteritis). In: Hashimoto H, chair. Treatment manual for intractable vasculitis. Intractable Vasculitis Research Group of the MHLW Specific Disease Research Project in 2002. 2002; 13-18 (in Japanese).
98. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. J Rheumatol 2000; 27: 1484-1491.
99. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo- controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54: 3310-3318.
100. Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85: 1061-1064.
101. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo- controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-1318.
102. Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-114.
103. Spiera RF, Kupersmith M, Paget S, Spiera H. Vision loss in giant cell arteritis patients treated with alternate-day corticosteroids: Comment on the article by Hoffman et al. Arthritis Rheum 2003; 48: 1159-1160; author reply 1160-1161.
104. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternateday corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Ann Intern Med 1975; 82: 613-618.
105. Bengtsson BA, Malmvall BE. An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis. Acta Med Scand 1981; 209: 347-350.
106. Rüegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983; 25: 615-620.
107. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19: 495-501.
108. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003; 62: 373-374.
109. Airò P, Antonioli CM, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002; 41: 347-349.
110. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases. Arthritis Rheum 2001; 44: 2933-2935.
111. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroidinduced remission of giant cell arteritis: A randomized trial. Ann Intern Med 2007; 146: 621-630.
112. Kussmaul A, Maier R. Über eine bisher nicht beschribene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeineer Muskellähmung einhergeht. Dtsh Arch Klin Med 1866; 1: 484-517 (in Germany).
113. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
114. Wegener F. Über eine eigenartige rhinogene Guranulomatose mit besonderer beteilgung des Arteriensystems under der Nieren. Beitr Pathol Anat 1939; 102: 36-68 (in Germany).
115. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27: 277-301.
116. Tamakoshi A, Kawamura T, Ohno Y, Hashimoto S, Minowa M, Inaba Y, et al. Estimated number of patients receiving treatment benefits for intractable diseases according to nationwide epidemiological surveys. Jpn Med J 1997; 3843: 25-28 (in Japanese).
117. Nakabayashi K. Subcommittee report on the epidemiology, prognosis and QOL of patients with medium- or small-vessel vasculitis. In: Hashimoto H, chair. Report by the Intractable Vasculitis Research Group of the MHLW Specific Immune Disease Study Group in 1998. 1999; 38-48 (in Japanese).
118. Arkin A. A clinical and pathological study of periarteritis nodosa: A report of 5 cases, one histologically healed. Am J Pathol 1936; 6: 401-427.
119. Selga D, Mohammad A, Sturfelt G, Segelmark M. Polyarteritis nodosa when applying the Chapel Hill nomenclature: A descriptive study on ten patients. Rheumatology (Oxford) 2006; 45: 1276-1281.
120. MacLaren K, Gillespie J, Shrestha S, Neary D, Ballardie FW. Primary angiitis of the central nervous system: Emerging variants. QJM 2005; 98: 643-654.
121. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg- Strauss syndrome: A prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28.
122. Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): Presentation and outcomes in 24 patients. Am J Med 2002; 112: 386-391.
123. Segelmark M, Selga D. The challenge of managing patients with polyarteritis nodosa. Curr Opin Rheumatol 2007; 19: 33-38.
124. Stanson AW, Friese JL, Johnson CM, McKusick MA, Breen JF, Sabater EA. Polyarteritis nodosa: Spectrum of angiographic findings. Radiographics 2001; 21: 151-159.
125. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-678.
126. Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67: 941-947.
127. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc 1980; 55: 146-155.
128. Guillevin L, Merrouche Y, Gayraud M, Jarrousse B, Royer I, Léon A, et al. Periarteritis nodosa related to hepatitis B virus: Determination of a new therapeutic strategy: 13 cases. Presse Med 1988; 17: 1522-1526 (in French).
129. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313-322.
130. Nakabayashi K, Hashimoto H. Guidelines for the treatment of ANCA-related vasculitis. In: Hashimoto H, chair. Intractable Vasculitis Research Group of the MHLW Specific Disease Research Project in 2002. 2002; 19-23 (in Japanese).
131. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg- Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-1297.
132. Guillevin L, Cohen P, Mahr A, Aréne JP, Mouthon L, Puéchal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49: 93-100.
133. Information Center for Japan Intractable Disease. Information from the Immune Disorder Study Group (Intractable Vasculitis Study Group): Table of cyclophosphamide doses by renal function. http: //www.nanbyou.or.jp/sikkan/025_2_i.htm (in Japanese)
134. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001; 13: 48-55.
135. Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Généreau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-1645.
136. Terada Y, Owada A, Shinohara S, Matsui N, Kawada K, Fujiwara H, et al. Combined treatment of plasmapheresis and methylprednisolone pulse therapy to polyarteritis nodosa with rapidly progressive glomerulonephritis. Nippon Naika Gakkai Zasshi 1988; 77: 494-498 (in Japanese).
137. Guillevin L, Lhote F. Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1998; 41: 2100-2105.
138. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
139. Scott DG, Watts RA. Systemic vasculitis: Epidemiology, classification and environmental factors. Ann Rheum Dis 2000; 59: 161-163.
140. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/ BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-753.
141. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018-2027.
142. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
143. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-429.
144. Yoshida M. Wegener's granulomatosis. In: Ozaki S, Yoshiki T, editors. Atlas of arteritis. Intractable Vasculitis Study Group of the MHLW Intractable Disease Treatment Research Project in 2005. 2005; 19-20 (in Japanese).
145. Yoshida M. Wegener's granulomatosis: Pathogenesis, pathophysiology, and therapy. Nippon Rinsho 2006; 64(Supple 2): 460-466 (in Japanese).
146. Hashimoto H, Yoshida M. In: Hashimoto H, chair. Treatment manual for intractable vasculitis. Intractable Vasculitis Research Group of the MHLW Specific Disease Research Project. 2002; 30 (in Japanese).
147. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al. Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. J Allergy Clin Immunol 2006; 117: 1292-1302.
148. Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, et al. Treatment of Churg-Strauss syndrome with highdose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004; 92: 80-87.
149. Saulsbury FT. Henoch-Schönlein purpura in children: Report of 100 patients and review of the literature. Medicine (Baltimore) 1999; 78: 395-409.
150. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 1990; 33: 1114-1121.
151. Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-623.
152. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins: A report of 86 cases. Am J Med 1974; 57: 775-788.
153. Braun GS, Horster S, Wagner KS, Ihrler S, Schmid H. Cryoglobulinaemic vasculitis: Classification and clinical and therapeutic aspects. Postgrad Med J 2007; 83: 87-94.
154. Bevans M, Nadell J, Demartini F, Ragan C. The systemic lesions of malignant rheumatoid arthritis. Am J Med 1954; 16: 197-211.